EUVIMEDObjevte EUVIMED
Crossref

Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series

Philippe Taieb iD, Marco Frazzetto iD, Pedro Soares Teixeira, Steven J Filby iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70036 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2025. Written by Philippe Taieb and 3 co-authors. Institution: Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Major MEDLINE topics: Atrial Appendage, Atrial Fibrillation, Cardiac Catheterization, Stroke. Cited 3 times so far (Crossref); 26 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Left atrial appendage closure (LAAC) is a well‐established alternative for stroke prevention in patients with atrial fibrillation (AF) who are not suitable for long‐term anticoagulation. The WATCHMAN FLX Pro 40 mm device is a novel advancement featuring a fluoropolymer coating to enhance thromboresistance and a size expansion to accommodate larger left atrial appendages (LAA). However, clinical data on this new device remains limited.

Objective

This study presents the first case series evaluating the procedural success, safety, and early outcomes of the 40 mm WATCHMAN FLX Pro device.

Methods

A total of nine patients underwent LAAC with the 40 mm WATCHMAN FLX Pro between July and November 2024. Pre‐procedural imaging, intraoperative guidance, procedural outcomes, and follow‐up imaging were analyzed. Procedural success was defined by the successful deployment of the device meeting “PASS” criteria, with no major complications.

Results

The study demonstrated a 100% procedural success rate, with all patients undergoing same‐day discharge. No procedural or periprocedural complications were observed. Follow‐up imaging at 4 months (available for 88.9% of patients) revealed no high‐grade device‐related thrombus (DRT), though some cases exhibited peridevice leaks, predominantly minor subfabric leaks.

Conclusion

The 40 mm WATCHMAN FLX Pro expands LAAC treatment options for patients with larger LAA anatomy, demonstrating a favorable safety and efficacy profile in this early experience. Larger studies with long‐term follow‐up are needed to validate these findings.

Subjects

MeSH terms (MEDLINE)

Atrial AppendageAtrial FibrillationCardiac CatheterizationStrokeAgedAged, 80 and overFemaleHumansMaleMiddle AgedProsthesis DesignRetrospective StudiesTime FactorsTreatment Outcome

Author keywords

WATCHMAN FLX PRO 40mmatrial fibrillationintracardiac echocardiography (ICE)‐guided LAACleft atrial appendage closure (LAAC)stroke prevention

Authors and institutions

  • Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

ORCID profiles: Philippe Taieb, Marco Frazzetto, Steven J Filby

Cite

APA

Taieb, P., Frazzetto, M., Teixeira, P. S., & Filby, S. J. (2025). Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70036

Vancouver

Taieb P, Frazzetto M, Teixeira PS, Filby SJ. Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70036

BibTeX
@article{Taieb2025,
  author = {Taieb, Philippe and Frazzetto, Marco and Teixeira, Pedro Soares and Filby, Steven J},
  title = {Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70036}
}
Start for free →